Duopa FDA Approval History
Duopa (carbidopa and levodopa) is an aromatic amino acid decarboxylation inhibitor and aromatic amino acid combination formulated as an enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.
Development timeline for Duopa
|Oct 19, 2022||BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled|
|Jan 12, 2015||Approval FDA Approves Duopa (carbidopa and levodopa) Enteral Suspension for Parkinson's Disease|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.